Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials

INTRODUCTION: In three phase III randomized controlled trials, ceftaroline fosamil was shown to be non-inferior to vancomycin plus aztreonam for the treatment of complicated skin and soft tissue infections (cSSTIs). This exploratory analysis evaluated the impact of underlying comorbidities on clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilcox, Mark, Yan, Jean Li, Gonzalez, Pedro L., Dryden, Matthew, Stone, Gregory G., Kantecki, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847533/
https://www.ncbi.nlm.nih.gov/pubmed/34741280
http://dx.doi.org/10.1007/s40121-021-00557-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847533/
https://www.ncbi.nlm.nih.gov/pubmed/34741280
http://dx.doi.org/10.1007/s40121-021-00557-w

Ejemplares similares